Lindis Blood Care
Lindis Blood Care is a medical technology company dedicated to revolutionizing blood management during cancer surgeries. They develop innovative medical devices, such as CATUVAB®, to reliably remove tumor cells from intraoperative blood, enabling safe autologous blood transfusions and reducing risks associated with donor blood. Their mission is to improve patient outcomes and safety in oncological procedures by providing cost-effective and easy-to-integrate solutions.
Industries
Nr. of Employees
small (1-50)
Lindis Blood Care
Neuendorfstrasse 18b, D-16761 Hennigsdorf, Germany
Patents
Products
Medical device kit for removal of EpCAM-positive tumor cells from intraoperative blood
A kit combining a trifunctional/bispecific antibody reagent and leukocyte-depletion filtration components intended to aggregate and remove EpCAM-positive tumor cells from collected intraoperative blood to enable autologous erythrocyte concentrate retransfusion.
Medical device kit for removal of EpCAM-positive tumor cells from intraoperative blood
A kit combining a trifunctional/bispecific antibody reagent and leukocyte-depletion filtration components intended to aggregate and remove EpCAM-positive tumor cells from collected intraoperative blood to enable autologous erythrocyte concentrate retransfusion.
Services
Engagement with potential international licensing partners and commercial partners to support distribution and market entry outside Europe.
Engagement with potential international licensing partners and commercial partners to support distribution and market entry outside Europe.
Expertise Areas
- Medical device development for intraoperative blood processing
- Clinical trial management and multicenter clinical studies
- Antibody-based cell-capture platform development
- Patient blood management (autologous transfusion workflows)
Key Technologies
- Trifunctional/bispecific antibody platform for cell aggregation
- EpCAM-targeted cell capture
- Leukocyte-depletion filtration
- Intraoperative blood salvage (IBS / machine autotransfusion) integration
News & Updates
Funding round supported by High-Tech Gründerfonds (HTGF), Brandenburg Kapital and several private investors, showing their continued commitment. Funds to be mainly used to complete ongoing REMOVE study with CATUVAB®, extend clinical program, complete CE marking procedure, start FDA market application process and support partnering activities.
Funding round supported by High-Tech Gründerfonds (HTGF), Brandenburg Kapital and several private investors, showing their continued commitment. Funds to be mainly used to complete ongoing REMOVE study with CATUVAB®, extend clinical program, complete CE marking procedure, start FDA market application process and support partnering activities.
Successful closure of follow-on financing round
Lindis Blood Care successfully closed a follow-on financing round supported by key investors, enabling further development and clinical validation of CATUVAB®.
Positive top-line results from clinical certification study REMOVE
The clinical study assessing CATUVAB® for tumor cell removal in cancer surgeries showed that the device is safe and effective, meeting all primary and secondary endpoints with high statistical significance.
Funding round supported by High-Tech Gründerfonds (HTGF), Brandenburg Kapital and several private investors, showing their continued commitment. Funds to be mainly used to complete ongoing REMOVE study with CATUVAB®, extend clinical program, complete CE marking procedure, start FDA market application process and support partnering activities.
Funding round supported by High-Tech Gründerfonds (HTGF), Brandenburg Kapital and several private investors, showing their continued commitment. Funds to be mainly used to complete ongoing REMOVE study with CATUVAB®, extend clinical program, complete CE marking procedure, start FDA market application process and support partnering activities.
Successful closure of follow-on financing round
Lindis Blood Care successfully closed a follow-on financing round supported by key investors, enabling further development and clinical validation of CATUVAB®.
Positive top-line results from clinical certification study REMOVE
The clinical study assessing CATUVAB® for tumor cell removal in cancer surgeries showed that the device is safe and effective, meeting all primary and secondary endpoints with high statistical significance.